 |
|
|
|
 |
|
|
| Article 1 to 10 out of 36 concerning Bayer AG
|
-
BRAIN and Bayer Schering Pharma co-operate on biotechnological steroid-production
(04 Feb 2010)
BRAIN AG and Bayer Schering Pharma AG co-operate in the field of production process optimisation of steroid compounds. The goal of the collaboration is the energy-efficient and thus sustainable fermentative production of steroid compounds using ...
-
Fluidigm and Bayer Cropscience enter global agreement for marker-assisted breeding and quality control
(29 Jan 2010)
Fluidigm Corporation announced it has entered into a multi-year agreement with Bayer CropScience to supply integrated fluidic circuits (IFCs) and instrumentation to Bayer CropScience's global operations. Bayer CropScience will be using Fluidigm ...
-
Cellectis grants Bayer HealthCare license to use homologous recombination patents
(15 Jan 2010)
Cellectis S.A. has announced that Bayer HealthCare has acquired a license to use Cellectis’ patent family WO9011354 covering homologous recombination aimed to introduce new features into the genome. This global license includes the use of the ...
-
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
(08 Dec 2009)
Bayer CropScience and FuturaGene PLC have entered into a license agreement for a drought tolerance technology. The agreement grants Bayer CropScience exclusive worldwide rights to utilize a FuturaGene drought tolerance technology in cotton. ...
-
Bayer Starts Phase III Trial with Florbetaben
(03 Dec 2009)
Detection of beta-Amyloid plaques in Alzheimer patients possible
Bayer Schering Pharma AG is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced ...
-
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
(27 Oct 2009)
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractor...
-
Bayer CropScience first to sequence the entire genome of rapeseed/canola
(14 Oct 2009)
Bayer CropScience announced that it has sequenced the entire genome of rapeseed/canola (Brassica napus) and its constituent genomes present in Brassica rapa and Brassica oleracea. This provides Bayer with a unique level of insight into the ...
-
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
(21 Sep 2009)
Bayer CropScience is accelerating the extension of its biotech and seed business. Following a record year in 2008, the company is continuing its strategy of expansion, aiming systematically to expand its fast-growing business in seed and plant ...
-
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
(17 Sep 2009)
Werner Wenning (62), Bayer AG CEO since 2002, is to extend his contract of service by eight months to September 30, 2010, a few weeks before his 64th birthday. In its meeting on Tuesday, Bayer’s Supervisory Board appointed Netherlands-born Dr. ...
-
Bayer CropScience and Performance Plants Inc. sign license agreement on drought-tolerant cotton
(03 Sep 2009)
Bayer CropScience AG and Performance Plants Inc. have entered into an exclusive licensing agreement for the development and commercialization of drought-tolerant cotton using Performance Plants’ Yield Protection Technology® (YPT). The agreement ...
|
|
|
|
|
Top